Alterity Therapeutics Limited
PRNAF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | -0.00 | -0.01 |
| FCF Yield | -6.90% | -16.96% | -60.56% | -22.66% |
| EV / EBITDA | -0.32 | -3.37 | -0.07 | -1.18 |
| Quality | ||||
| ROIC | -8.44% | -94.86% | -93.36% | -37.02% |
| Gross Margin | 98.33% | 96.04% | 94.46% | 94.90% |
| Cash Conversion Ratio | – | – | 0.64 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.23% | 13.18% | 6.48% | -7.82% |
| Free Cash Flow Growth | 53.40% | 37.68% | -80.22% | 55.50% |
| Safety | ||||
| Net Debt / EBITDA | 9.29 | 0.59 | 0.96 | 1.83 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,330.74 | -2,583.68 | -275.00 | -3,095.60 |